FDA awards orphan drug designation to Avstera's HDAC6 inhibitor AVS-100 for stage IIB-IV melanoma

Nov. 14, 2022

The FDA has awarded orphan drug designation to Avstera Therapeutics Corp.'s AVS-100 for the treatment of stage IIB through IV melanoma.

BioWorld Science Cancer FDA Orphan drug

Today's news in brief

BioWorld

BioWorld briefs for Nov. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 14, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...